BioStock: Stayble Therapeutics prepares for partnership
Stayble Therapeutics focuses partly on developing its candidate STA363, which is currently undergoing phase IIb, and partly on preparing for the next target – a future partnership to take the candidate through phase III studies and all the way to the market. BioStock contacted Jane Buus Laursen, board member of Stayble Therapeutics, to learn more about the partnering opportunities for the company and what the market landscape for STA363 looks like.
Read the full interview with board member Jane Buus Laursen at biostock.se:
This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/